Table 4B.
Impact of cumulative use of antibiotics on overall survival
| Name of covariates | p value | Hazard ratio (95% CI) |
|---|---|---|
| Participate in trials, yes vs. no | .002 | 0.559 (0.384–0.812) |
| Number of metastatic sites | ||
| 2 vs. 0/1 | .697 | 1.120 (0.633–1.983) |
| 3+ vs. 0/1 | .004 | 2.289 (1.304–4.019) |
| ECOG performance status | ||
| 1 vs. 0 | .002 | 1.812 (1.238–2.651) |
| 2+ vs. 0 | .00003 | 3.027 (1.801–5.090) |
| Comorbities, yes vs. no | .020 | 1.523 (1.069–2.169) |
| Cumulative use of antibiotics | ||
| Single course vs. no | .294 | 1.259 (0.819–1.934) |
| Cumulative courses vs. no | .009 | 1.904 (1.178–2.078) |
Abbreviations: CI, confidence interval; ECOG: Eastern Cooperative Oncology Group.